Skip to main content
. 2018 Jun 15;6(1):e000516. doi: 10.1136/bmjdrc-2018-000516

Table 2.

Covariate balance between medication categories before and after inverse probability of treatment-weighted standardization

Covariate Maximum between-group standardized differencebefore weighting (%) Maximum between-group standardized differenceafter weighting (%)
Age 40.6 5.4
Male 10.6 7.4
Race
 White 13.8 5.2
 Black 15.6 5.7
 Asian 8.1 8.1
 Pacific Islander 4.1 2.4
 Native American 8.4 4.5
Family history of CAD 11.1 2.5
Tobacco 8.0 7.0
Hypertension 11.6 3.4
Hyperlipidemia 9.0 5.0
BMI 13.2 2.2
Framingham risk score 19.8 5.8
PAD 15.7 5.9
CHF 30.8 6.1
COPD 6.2 2.5
CKD 75.7 14.7
Dialysis 26.1 14.0
Depression 13.1 2.5
PTSD 14.1 4.3
Presentation
 Stable angina 6.9 7.5
 Positive functional study 15.7 4.2
 Ischemic heart disease 5.9 1.7
 Chest pain 13.8 2.0
Postangiography revascularization
 None 10.7 4.6
 PCI 6.2 3.5
 CABG 8.0 4.2
Baseline HbA1c 32.4 4.8
Diabetes duration 16.6 5.3

BMI, body mass index; CABG, coronary artery bypass graft; CAD, coronary artery disease; CHF, congestive heart failure; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; HbA1c, hemoglobin A1c; PAD, peripheral arterial disease; PCI, percutaneous coronary intervention; PTSD, post-traumatic stress disorder.